Advertisement

Search Results

Advertisement



Your search for ,her matches 3362 pages

Showing 301 - 350


Reframing DCIS as an Opportunity for Cancer Prevention

We have been taught that early cancer detection and treatment save lives. The way to cure cancer is to find it early and treat it aggressively. The public has subscribed to this approach in our struggle to “eradicate cancer.” In certain disease types, there is merit to this philosophy. The ability...

colorectal cancer
pancreatic cancer

Jennifer Yon-Li Wo, MD, on Colorectal and Pancreatic Cancers: New Findings on SBRT With Ipilimumab and Nivolumab

Jennifer Yon-Li Wo, MD, of Massachusetts General Hospital, discusses the local failure rate of non-ablative hypofractionated radiation therapy in combination with the immune checkpoint inhibitors ipilimumab and nivolumab compared to ablative SBRT to treat metastatic microsatellite-stable colorectal ...

breast cancer

Expert Point of View: Laura Huppert, MD

Invited discussant Laura Huppert, MD, of the University of California, San Francisco, Comprehensive Cancer Center, focused her remarks on the need for biomarkers for selection of immunotherapy as part of neoadjuvant chemotherapy for hormone receptor–positive, HER2-negative breast cancer. “Hormone...

multiple myeloma

Expert Point of View: Cynthia E. Dunbar, MD

In a press briefing at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, Cynthia E. Dunbar, MD, ASH Secretary and Chief of the Translational Stem Cell Biology Branch, Intramural Research Program of the National Heart, Lung, and Blood Institute, offered her thoughts on...

multiple myeloma

Canadian Study Shows Myeloma Outcomes in the Real World May Be Worse Than Clinical Trials Suggest

Patients with multiple myeloma treated in the “real world” had worse outcomes than patients who received the same treatment on clinical trials, according to research presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition.1 In a pooled analysis of clinical trial...

cardio-oncology

Use of Direct Oral Anticoagulant Agents in Active Cancer: Meta-Analysis

In a systematic review and meta-analysis reported in JACC: CardioOncology, Fujisaki et al found no significant differences among direct oral anticoagulant agents (DOACs) in the prevention of recurrent venous thromboembolism (VTE) associated with active cancer, whereas significant differences in...

breast cancer
issues in oncology

A New Approach to Identifying Consumer Products That Contain Cancer-Causing Chemicals

Researchers may have uncovered a novel strategy to predict whether synthetic chemicals may cause breast cancer by examining their specific traits, according to a recent study published by Kay et al in Environmental Health Perspectives. Background The incidence of breast cancer—the most common...

lung cancer

EGFR-Mutated Early-Stage NSCLC

This is Part 3 of New Directions in Nonmetastatic Non–Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable.   In this video, Drs. Heather Wakelee, Tina Cascone, and Marina Garassino discuss the management of EGFR-mutated...

hematologic malignancies
issues in oncology

Sara Khan, DO, on the Gender Gap in Receiving NIH Grants for Hematology Research

Sara Khan, DO, of the University of South Florida Morsani College of Medicine and HCA Healthcare, discusses her findings showing that women received only 33% of grants from the National Institutes of Health from 2012 to 2022 in nonmalignant hematologic research. Although some agencies have made...

lung cancer

Antibody-Drug Conjugate Ifinatamab Deruxtecan Shows Robust Activity in Refractory Small Cell Lung Cancer

The antibody-drug conjugate ifinatamab deruxtecan has demonstrated “robust and durable efficacy” in patients with heavily pretreated small cell lung cancer, according to a subset analysis of the DS7300-A-J101 trial presented at the International Association for the Study of Lung Cancer 2023 World...

skin cancer

Melanoma in Younger Individuals

This is Part 4 of Evolving Skin Cancer Management, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable.   In this video, Drs. Pauline Funchain, Alison Vidimos, and Lisa Zaba review the case of a 32-year-old patient who recently gave birth to her first...

skin cancer

Nonsurgical Approaches to Basal Cell Carcinoma

This is Part 1 of Evolving Skin Cancer Management, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable.   In this video, Drs. Pauline Funchain, Alison Vidimos, and Lisa Zaba discuss nonsurgical treatment options for basal cell carcinoma. The patient is a...

W. Kimryn Rathmell, MD, PhD, Begins Work as 17th Director of the NCI

On December 18, W. Kimryn Rathmell, MD, PhD, began her work as the 17th Director of the National Cancer Institute (NCI). Dr. Rathmell was selected by President Biden to succeed Monica M. Bertagnolli, MD, FACS, FASCO, who left NCI to become the Director of the National Institutes of Health (NIH) on...

multiple myeloma

Danai Dima, MD, on Multiple Myeloma: Update on Safety and Efficacy of Teclistamab

Danai Dima, MD, of the Taussig Cancer Institute, Cleveland Clinic, discusses teclistamab-cqyv, a B-cell maturation antigen approved in October 2022 for patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. Dr. Dima and her team evaluated the...

issues in oncology
supportive care

Expert Point of View: Kerin B. Adelson, MD, MHCDS

Discussant of these abstracts on the Oncology Care Model (OCM), Kerin B. Adelson, MD, MHCDS, Chief Quality and Value Officer at The University of Texas, MD Anderson Cancer Center, suggested the OCM was beneficial for both patients and health professionals despite the lack of clear positive ...

issues in oncology

On Mark Cuban and the Chemotherapy Crisis

Although significant progress has been made to reduce the gap in health outcomes of minority or underserved patients, meaningful steps forward still need to be made to improve health disparities. Countless studies have shown, in general, that affluent White individuals have better health outcomes...

Supportive Parents and Early Love of Science Lead to a Career in Hematology Oncology for Nina Shah, MD

In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Nina Shah, MD, Global Head of Multiple Myeloma Clinical Development and Strategy, Hematology, Oncology Research and Development at AstraZeneca. She is a hematologist who specializes in...

Remembering Cancer Prevention and Health Equity Champion Worta J. McCaskill-Stevens, MD, MS

ASCO and the oncology community are deeply saddened by the death of medical oncologist Worta J. McCaskill-Stevens, MD, MS, on November 15, 2023. Dr. McCaskill-Stevens served as Chief of the National Cancer Institute (NCI) Community Oncology and Prevention Trials Research Group and Director of the...

breast cancer

Recipients of 2023 Susan G. Komen Breast Cancer Awards Honored

Susan G. Komen presented its 2023 Breast Cancer Awards to four physician-scientists and one research advocate for their contributions to advancing breast cancer discoveries and improving patient outcomes. The five recipients were recognized at the Susan G. Komen Breast Cancer Awards event in San...

breast cancer
supportive care

Exercise May Boost Quality of Life for Patients With Metastatic Breast Cancer

Patients with metastatic breast cancer who took part in a 9-month structured exercise program reported less fatigue and an improved quality of life compared to those who did not participate in the exercise program, according to results from the PREFERABLE-EFFECT trial presented at the 2023 San...

breast cancer

Tucatinib Plus T-DM1 May Benefit Patients With Advanced or Metastatic HER2-Positive Breast Cancer

A combination of two HER2-targeted drugs—tucatinib and ado-trastuzumab emtansine (T-DM1), extended progression-free survival among patients with unresectable, locally advanced, or metastatic HER2-positive breast cancer compared with T-DM1 alone, according to results from the HER2CLIMB-02 trial...

Expert Point of View: Zofia Piotrowska, MD

Zofia Piotrowska, MD, of the Massachusetts General Hospital/Harvard Medical School, Boston, noted that MARIPOSA and MARIPOSA-2 are “two well-designed, randomized phase III trials, each meeting its primary endpoints and representing important advances for patients with EGFR-mutant lung cancer.”...

lung cancer

Antibody-Drug Conjugate Ifinatamab Deruxtecan Shows ‘Robust’ Activity in Refractory Small Cell Lung Cancer

The antibody-drug conjugate ifinatamab deruxtecan has demonstrated “robust and durable efficacy” in patients with heavily pretreated small cell lung cancer, according to a subset analysis of the DS7300-A-J101 trial presented at the International Association for the Study of Lung Cancer 2023 World...

National Academy of Medicine Elects New Members

The National Academy of Medicine recently announced the election of 100 members during its annual meeting, including 10 international members. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated major...

integrative oncology

Society for Integrative Oncology Celebrates 20 Years of Excellence

Guest Editor’s Note: The Society for Integrative Oncology (SIO) held its 20th international conference in Banff, Alberta, Canada. The conference focused on the theme “Integrative Oncology as Standard of Care: The Time Is Now.” The mood was festive, and the weather cooperated with warm temperatures, ...

breast cancer

From a Small Town in the Rust Belt, Dennis J. Slamon, MD, PhD, Plays a Big Role in Changing the Face of Breast Cancer Treatment

In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Dennis J. Slamon, MD, PhD, one of the principals in the discovery and development of trastuzumab—the first monoclonal antibody used against an oncogene that altered our entire approach...

lung cancer

Small Study Identifies Safe, Effective Radiation Dose to Add to Neoadjuvant Chemotherapy and Durvalumab

Low-dose radiotherapy in combination with the monoclonal antibody durvalumab and chemotherapy as neoadjuvant therapy was well tolerated in patients with potentially resectable stage III non–small cell lung cancer (NSCLC), according to a small study conducted in China and presented at the...

ASCO Applauds Appointment of W. Kimryn Rathmell, MD, PhD, as Next NCI Director

On November 17, President Joe Biden announced the appointment of W. Kimryn Rathmell, MD, PhD, Chair of Medicine at Vanderbilt University Medical Center and Physician-in-Chief for Vanderbilt University Adult Hospital and Clinics, as his choice for Director of the National Cancer Institute (NCI). Dr. ...

issues in oncology

The Progress of Delivering High-Quality Cancer Care Takes Center Stage at Workshop

ASCO and the National Cancer Policy Forum cohosted a workshop on October 5–6, 2023, to mark the 10-year anniversary of the Institute of Medicine (IOM) consensus report, Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis.1 The National Cancer Policy Forum is a...

ASCO Applauds Confirmation of Monica Bertagnolli, MD, FACS, FASCO, as NIH Director

On November 7, the Senate overwhelmingly confirmed Monica M. Bertagnolli, MD, FACS, FASCO, by a vote of 62 to 36, as the 17th Director of the National Institutes of Health (NIH). Dr. Bertagnolli is currently Director of the National Cancer Institute (NCI). She served as ASCO President from 2018 to ...

lung cancer
issues in oncology

Low-Dose CT Screenings Leading to Early Diagnosis May Improve Long-Term Lung Cancer Survival Rates

Diagnosing early-stage lung cancer with low-dose computed tomography (CT) screening may improve 20-year survival rates, according to a recent study published by Henschke et al in Radiology. The new findings demonstrated the significance of routine early screenings to detect tumors when they are...

lymphoma
issues in oncology

Novel Strategy May Improve Outcomes in Patients With Treatment-Resistant DLBCL

Researchers have found that a DNA repair–facilitating mechanism may be responsible for a tumor’s treatment resistance and could be treated with a combination of chemotherapies, according to a recent study published by Marullo et al in Cancer Research. The mechanism involves the shuttling of...

lung cancer

Comparing Two Radiation Therapy Techniques for Locally Advanced NSCLC: Focus on Toxicity

Intensity-modulated radiation therapy (IMRT) reduced the risk of toxicity to the lungs and radiation exposure to the heart vs three-dimensional conformal radiotherapy (3D-CRT) for the treatment of locally advanced non–small cell lung cancer (NSCLC), according to a planned long-term prospective...

leukemia

Getting a Cancer Diagnosis at Age 16 Has Taught Me to Live in the Present

I have been fascinated with death since I was 3 years old. I remember going to my great-grandfather’s funeral and asking my mother where my great-grandfather was. She said he is in heaven. I asked her if I were going to heaven, too, and she said, “Yes, but not for a long time.” Today, I don’t...

global cancer care

From Humble Beginnings, Elisabete Weiderpass, MD, MSc, PhD, Distinguishes Herself as First Woman to Head the IARC

In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Elisabete Weiderpass, MD, MSc, PhD, a Brazilian cancer researcher who is a naturalized Swedish and Finnish citizen. She is an expert in cancer epidemiology and cancer prevention. In...

Expert Point of View: Helena Linardou, MD, PhD

Helena Linardou, MD, PhD, Director of the 4th Department of Oncology and the Comprehensive Clinical Trials Center, Metropolitan Hospital, Athens, served as discussant of the session on antibody-drug conjugates at the 2023 World Conference on Lung Cancer. Calling antibody-drug conjugates “the next...

breast cancer
issues in oncology

Patient Education Materials on Breast Cancer May Be Difficult to Access

Investigators have discovered that reliable educational materials about breast cancer surgery may be difficult to access and are often presented at much higher reading levels than recommended, according to the findings of two new studies presented by Brennan et al and Satarasinghe et al at the...

breast cancer

SOFT Analysis: Breast Cancer Index May Identify Which Patients Need Ovarian Suppression

In an analysis of the SOFT trial, the Breast Cancer Index accurately identified premenopausal women with hormone receptor–positive early breast cancer who may benefit from ovarian function suppression in addition to adjuvant endocrine therapy. The findings were reported by Ruth O’Regan, MD, Chair...

palliative care

ASCO Launches New Webinar: Making Palliative Care a Part of Your Oncology Practice

ASCO President Lynn Schuchter, MD, FASCO, has made access to palliative and supportive care among patients with cancer a central focus of her presidential term. Although not all cancer clinicians can be palliative care specialists, because palliative and supportive care are so essential to every...

sarcoma

A Diagnosis of Ewing Sarcoma Altered the Trajectory of My Life

In August 2014, just a few weeks after my 15th birthday, my body began sending me a lot of worrisome signals that life as I knew it would soon be over. The year before, I had developed a hematoma in my right femur, which was resolved with surgery. But now the pain I was experiencing in that leg was ...

From a Sleepy Town in Pakistan, Seema A. Khan, MD, MPH, Emerges as a Leader in Surgical Oncology

In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Seema A. Khan, MD, MPH, Professor of Breast Cancer Surgery at Northwestern Medicine, Feinberg School of Medicine. Along with her surgical and academic pursuits, Dr. Khan is an active...

National Inventors Hall of Fame Recognizes Jennifer Doudna, PhD; Emmanuelle Charpentier, PhD; and Angela Hartley Brodie, PhD

The National Inventors Hall of Fame (NIHF) recognizes the enduring legacies of exceptional U.S. patent holders on an annual basis. On October 26, 2023, three female inductees will be recognized for their extraordinary contributions to cancer care and clinical research. Biochemist Jennifer...

supportive care
pain management
palliative care
symptom management

Using Recent Diagnostic Scans May Cut Time to Treatment for Patients Needing Urgent Palliative Radiotherapy

Using previously taken diagnostic computed tomography (CT) scans in place of CT simulation scans to plan simple palliative radiation treatments may substantially reduce the time spent waiting for urgent treatment, improving the patient experience, a new study suggests. Patients who may benefit from ...

gynecologic cancers

Sexual Activity and Vaginal Dilation Associated With Fewer Side Effects After Chemoradiation for Cervical Cancer

People who engage in sexual activity or vaginal dilation after chemoradiation for cervical cancer are at lower risk for long-term side effects, according to a new study from researchers in Austria. Findings of the EMBRACE study were presented by Kirchheiner et al at the 2023 American Society for...

lung cancer

The New Era of Perioperative Therapy in Non–Small Cell Lung Cancer

Recent developments in surgery and therapeutics are changing the perioperative approach to non–small cell lung cancer (NSCLC). These advances were discussed at the 2023 Debates and Didactics in Hematology and Oncology conference, sponsored by Emory University, by Jennifer W. Carlisle, MD, Assistant ...

gynecologic cancers
issues in oncology

Liquid Biopsies May Be Predictive of Cancer Recurrence Following Chemoradiation in Patients With Cervical Cancer

Two liquid biopsy tests designed to detect the human papillomavirus (HPV) in the blood may accurately identify patients at high risk of cervical cancer recurrence following the completion of chemoradiation, according to new findings presented by Han et al at the 2023 American Society for Radiation...

gynecologic cancers
issues in oncology

Gynecologic Cancer Misinformation May Be Widespread on TikTok

The majority of information related to gynecologic cancers on the social media platform TikTok may be misleading or inaccurate, according to a recent study published by Morton et al in Gynecologic Oncology.   Background “The intent of this study was to understand the needs of patients that may go...

breast cancer

Management of De Novo Metastatic Estrogen Receptor–Positive Breast Cancer

This is Part 3 of Ovarian Function Suppression in Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable.   In this video, Drs. Jame Abraham, Erin Roesch, and Azka Ali discuss the management of a patient with de novo metastatic estrogen...

27th Cancer Leadership Awards Recipients Announced by Friends of Cancer Research

Friends of Cancer Research recently announced its 2023 Cancer Leadership Awards honorees: Commissioner of the U.S. Food and Drug Administration (FDA), Robert Califf, MD, and Congresswoman Debbie Dingell (D-MI). Dr. Califf, recognized for his work in the field of cardiology and the broader medical ...

sarcoma
global cancer care

Catalyzing Change: Young Moroccan Oncologists Spearhead the Fight Against Sarcoma

The management of sarcoma presents several challenges because of its rarity and diverse subtypes, making accurate diagnosis and specialized treatment crucial. A multidisciplinary approach involving various experts from different cancer specialties is the optimal strategy to improve survival and...

Advertisement

Advertisement




Advertisement